World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
55427
World Ranking
5470
National Ranking
2946

Overview

Noopur Raje is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with significant contributions in hematology, oncology, molecular biology, genetics, and immunology.

Their scholarly output includes over 550 publications in medicine, with a notable emphasis on hematology (238 publications) and oncology (170 publications). Raje's work encompasses various interdisciplinary fields, integrating molecular biology and genetics into their studies.

Raje's research topics extensively cover:

  • Multiple Myeloma Research and Treatments
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • Cancer Treatment and Pharmacology
  • Monoclonal and Polyclonal Antibodies Research

The scientist has contributed to a variety of frequent publication venues including:

  • Clinical Lymphoma Myeloma & Leukemia (79 publications)
  • Blood (72 publications)
  • Journal of Clinical Oncology (26 publications)
  • Blood Advances (17 publications)
  • Leukemia (10 publications)

Among Raje's recent notable papers are:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results, 2023, Nature Medicine
  • Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma, 2022, New England Journal of Medicine
  • Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021, The Lancet Oncology

Raje's research collaborations include frequent co-authors such as:

  • Andrew J. Yee (86 joint publications)
  • Paul G. Richardson (52 joint publications)
  • Andrew R. Branagan (50 joint publications)
  • Nizar J. Bahlis (49 joint publications)
  • Nikhil C. Munshi (48 joint publications)

This body of work demonstrates Raje's active engagement in clinical and molecular research focused on blood cancers and targeted therapies, contributing to advancements in multiple myeloma treatment paradigms and immunotherapy approaches.

Best Publications

  • Multiple myeloma

    Noopur Raje;Kenneth C. Anderson

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

    Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje

  • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

    Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

    Teru Hideshima;Laurence Catley;Hiroshi Yasui;Kenji Ishitsuka

  • Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

    Loredana Santo;Teru Hideshima;Andrew L. Kung;Jen-Chieh Tseng

  • Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

    Klaus Podar;Yu-Tzu Tai;Faith E. Davies;Suzanne Lentzsch

  • Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

    Mariateresa Fulciniti;Pierfrancesco Tassone;Teru Hideshima;Sonia Vallet

  • Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

    Paul G. Richardson;David S. Siegel;Ravi Vij;Craig C. Hofmeister

  • Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

    Toshiaki Hayashi;Teru Hideshima;Masaharu Akiyama;Klaus Podar

  • Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

    Teru Hideshima;Hiroshi Ikeda;Dharminder Chauhan;Yutaka Okawa

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

    Noopur Raje;Evangelos Terpos;Wolfgang Willenbacher;Kazuyuki Shimizu

  • Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

    Güllü Topal Görgün;Gregory Whitehill;Gregory Whitehill;Jennifer L. Anderson;Jennifer L. Anderson;Teru Hideshima

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma

    M Fulciniti;S Vallet;S Ettenberg;X Shen

Frequent Co-Authors

Teru Hideshima
Teru Hideshima Harvard University
Paul G. Richardson
Paul G. Richardson Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Kenneth C. Anderson
Kenneth C. Anderson Harvard University
Dharminder Chauhan
Dharminder Chauhan Harvard University
Yu-Tzu Tai
Yu-Tzu Tai Harvard University
Shaji Kumar
Shaji Kumar Mayo Clinic
Klaus Podar
Klaus Podar Karl Landsteiner University of Health Sciences
Robert L. Schlossman
Robert L. Schlossman Harvard University
Constantine S. Mitsiades
Constantine S. Mitsiades Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a medical career in the USA opens the door to several related fields with flexible education options. Many students explore alternatives to traditional medicine, such as nursing, healthcare administration, nutrition, or nurse practitioner roles.

Prospective nurses may benefit from nursing schools that don't require teas or other entrance exams. This provides a streamlined path for those ready to begin their nursing journey without additional testing requirements.

For those interested in the administrative side of healthcare, there are healthcare administration degrees available online. These programs can be completed at an accelerated pace, preparing graduates for leadership positions in hospitals and clinics.

Registered nurses aiming to advance their practice can find rn to fnp bridge programs. These specialized paths enable working nurses to become Family Nurse Practitioners more efficiently.

Additionally, those keen on preventative healthcare and wellness may pursue online nutrition degrees. This prepares graduates for careers in nutritional counseling, dietetics, and public health.

Each of these pathways offers unique benefits and may align with your career goals in the wider healthcare sector.

Best Scientists Citing Noopur Raje

Trending Scientists

Recently Published Articles